The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to daridorexant for the treatment of insomnia disorder in patients ages 10 to younger than 18 years, according to an announcement from Idorsia Ltd.

About daridorexant and the FDA designation

Daridorexant is a dual orexin receptor antagonist (DORA) that selectively reduces wake drive by targeting the brain’s orexin signaling system, which helps regulate overactive wake signaling without broadly suppressing brain activity.

In a press release, Idorsia said it designed daridorexant with an optimized pharmacokinetic profile to provide efficacy throughout the night while minimizing residual exposure the following morning. The drug, marketed under the brand name QUVIVIQ, is approved for the treatment of insomnia in adults and is being studied for pediatric insomnia.

The FDA grants Breakthrough Therapy Designation to investigational therapies that may offer substantial improvement over available treatments for serious conditions. The designation provides increased interaction and guidance from the FDA on the development of daridorexant for children and adolescents.

According to Idorsia, the designation was supported by clinical evidence that includes trials published in The Lancet Neurology, which demonstrated improvements in sleep onset, sleep maintenance, and self-reported total sleep time in adults with insomnia. The company also reported that a Phase 2 pediatric study met its primary endpoint, showing a statistically significant, dose-dependent improvement in total sleep time, with the greatest benefit observed among participants with neurodevelopmental disorders.

No FDA-approved pharmacologic treatments are currently available for pediatric insomnia, and Idorsia plans to move forward with a Phase 3 development program.

About insomnia

Insomnia is a sleep disorder characterized by persistent difficulty falling asleep, staying asleep, or achieving restorative sleep despite adequate opportunity for sleep. Chronic insomnia is typically defined as symptoms occurring at least three times per week for three months or longer and can negatively affect daytime functioning, mood, cognition, and quality of life. An estimated 10% of adults experience chronic insomnia, and sleep difficulties are also common among children and adolescents.

Read more industry news from the AASM.